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Post-translational modiﬁcationirus E2 proteins is regulated by proteasomal degradation, and regulation of
degradation could contribute to the higher expression levels of E2 proteins observed in suprabasal layers of
differentiated skin. We have recently shown that the E2 proteins are modiﬁed by sumoylation [Wu Y-C, Roark
AA, Bian X-L, Wilson, VG (2008) Virol 378:329–338], and that sumoylation levels are up-regulated during
keratinocyte differentiation [Deyrieux AF, Rosas-Acosta G, Ozbun MA, Wilson VG (2007) J Cell Sci 120:125–
136]. These observations, coupled with the known ability of sumoylation to prevent proteasomal degradation
of certain proteins, suggested that this modiﬁcation might contribute to stabilizing E2 proteins in suprabasal
keratinocytes. Conditions that increased overall sumoylation were found to increase the intracellular
amounts of the HPV11, 16, and 18 E2 proteins. No effect of sumoylation was seen on E2 transcripts, and the
increased levels of E2 proteins resulted from a greatly increased half-life for the E2 proteins. In vitro studies
conﬁrmed that sumoylation could block the proteasomal degradation of the 16E2 protein. Interestingly, this
stabilization effect was indirect as it did not require sumoylation of 16E2 itself and must be acting through
sumoylation of a cellular target(s). This sumoylation-dependent, indirect stabilization of E2 proteins is a
novel process that may couple E2 levels to changes in the cellular environment. Speciﬁcally, our results
suggest that the levels of papillomavirus E2 protein could be up-regulated in differentiating keratinocytes in
response to the increased overall sumoylation that accompanies differentiation.
© 2009 Elsevier Inc. All rights reserved.IntroductionPapillomavirus E2 early proteins are key regulators of many viral
and cellular processes, including viral replication (Chiang et al., 1992;
Demeret et al., 1995; Stubenrauch et al., 1998), genome segregation
(McPhillips et al., 2006; You et al., 2004), and transcriptional control
(Demeret et al., 1997; Kovelman et al., 1996). The critical role of E2 in
viral transcription requires binding of E2 to the upstream regulatory
region (URR) in a concentration-dependent manner that regulates
early promoter expression. The regulation is positive when the E2
concentration is low, while early transcription is repressed when the
E2 concentration is high (Demeret et al., 1997). Therefore, changes in
E2 steady-state level during viral growth and persistence would be
expected to modulate the viral transcription program.
The life cycle of papillomaviruses is closely linked to the epithelial
differentiation schemeof the infectedhost keratinocyte (Longworth and
Laimins, 2004), and E2 proteins are found to accumulate to higher levels
in the suprabasal layers (Penrose and McBride, 2000; Stevenson et al.,
2000). Increased transcription during differentiation likely contributes
to at least part of the increase in E2 protein levels (Klumpp and Laimins,
1999;OzbunandMeyers,1998), though regulation at the level of protein
stability may also be involved. The stability of E2 proteins is regulatedWilson).
ll rights reserved.through the proteasome degradation pathway (Bellanger et al., 2001;
Penrose and McBride, 2000), and for the bovine papillomavirus (BPV)
E2 protein, phosphorylation of E2 by casein kinase II signals degradation
of E2 (Penrose et al., 2004). The critical phosphorylation event occurs
within a PEST sequences in E2, and phosphorylation of this PEST
sequence reduces its conformational stability which then targets E2 for
proteasomal degradation (Garcia-Alai et al., 2006). While HPV E2
proteins also are proteasomally degraded, less is known about signals
and regulation of this process. Recently, we demonstrated that HPV E2
proteins are modiﬁed by sumoylation, and that this modiﬁcation affects
transcriptional activity (Wu et al., 2008). Interesting, sumoylation has
alsobeen shown to affectprotein stability bothpositivelyandnegatively.
For proteins such as IκBα (Desterro et al.,1998), Smad4 (Lin et al., 2003),
and Huntingtin (Steffan et al., 2004), sumoylation stabilizes the protein
through direct competitionwith ubiquitin for a common lysine residue.
Alternatively, several proteins including APA-1 (Benanti et al., 2002),
HIF-1α (Bae et al., 2004), c-Myb(Bies et al., 2002), andKu70 (Yurchenko
et al., 2008), are protected from degradation by sumoylation through
poorly deﬁned mechanisms that do not involve competition with
ubiquitin for a common lysine residue. In contrast to these examples of
stabilization, for many proteins sumoylation may promote proteasomal
degradation by increasing ubiquitinylation through recruitment of
SUMO-dependent ubiquitin ligases (reviewed in Wilson and Heaton,
2008). As overall sumoylation is up-regulated during keratinocyte
differentiation (Deyrieuxet al., 2007), a possible linkbetweenE2protein
levels and sumoylation changes was examined in this study.
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transcription factors, where the small ubiquitin-related modiﬁer
(SUMO) is attached to the substrate proteins in a reversible manner
(Matunis et al., 1996). There are three principle SUMO proteins:
SUMO1, SUMO2, and SUMO3. The process and enzymes involved in
sumoylation are functionally similar to those enzymes catalyzing the
attachment of ubiquitin to its substrates (Hay, 2005). In the present
study, we demonstrate that increased in vivo sumoylation leads to
elevated levels of papillomavirus E2 protein. The increased E2 levels
were not due to transcriptional effects and did not require
sumoylation of E2 itself, indicating an indirect effect. Using a
reconstituted proteosomal degradation assay, sumoylation also
blocked HPV16E2 degradation in vitro. These results reveal a novel
mechanism for sumoylation-dependent stabilization of E2 proteins
that may tie E2 levels to host cell sumoylation changes during the cell
cycle, in response to environmental signals, or during keratinocyte
differentiation.
Results
Exogenous expression of the sumoylation components in vivo increases
intracellular levels of HPV E2 proteins
We recently demonstrated the papillomavirus E2 proteins are
sumoylated and showed that for HPV 16E2 there is a single
sumoylation site at lysine 292 (Wu et al., 2008). Those studies
utilized proteasome inhibitors to stabilize E2 and allow detection of
the low level of the sumoylated form of E2. However, during those
studies we observed that in the absence of proteasome inhibitor the
steady state level of 16E2 protein increased during co-expressionwith
sumoylation components, and the basis for that observation is
explored in this current study. Under the transfection conditions
used, co-expression of SUMO with Ubc9 led to increased overall
intracellular sumoylation (Fig. 1A) and speciﬁc sumoylation of known
target proteins, as exempliﬁed by C/EBP (Fig. 1B). Similarly, transfec-
tion of HPV16E2 along with SUMO3 and Ubc9 resulted in sumoylation
of E2 (Fig. 1C, lane 2), and also resulted in a large increase in theFig. 1. Expression of exogenous SUMO1 and Ubc9 enhances overall sumoylation as well
as sumoylation of speciﬁc targets. (A) HeLa cells were transfected with 3 μg of pcDNA5
(lane 1) or were co-transfected with 1.5 μg of pcDNA5/FRT/TO/SUMO1 and 1.5 μg of
Ubc9 (lane 2). Two days after transfection, total protein extracts were harvested and
then analyzed by immunoblotting with rabbit anti-SUMO1 serum. Introduction of
SUMO1 and Ubc9 led to a large increase in sumoylated products. Molecular weight
marker positions are indicated on the right. (B) The transfections in part (A) were
repeated with the additional transfection of 2 μg pcDNA3.1-C/EBPβ to each sample. The
immunoblot was analyzed with rabbit anti-C/EBPβ (Santa Cruz; 1:10,000 dilution). (C)
As in (B) except that 3 μg of pWEB-16E2 DNA was used rather than the pcDNA3.1-C/
EBPβ DNA. Immunoblotting for E2 was as described in Materials and methods.amount of unmodiﬁed E2 compared to transfection of E2 without
SUMO and Ubc9 (Fig. 1C, lane 1), suggesting that E2 expression is
affected by sumoylation levels. To further evaluate the effect of Ubc9
and various SUMO types, combination transfections experiments
were performed (Fig. 2A). With the transfection and immunoblot
exposure conditions used throughout this study, the sumoylated E2
band was quite faint so only the unmodiﬁed E2 form is shown in this
and subsequent ﬁgures. Likewise, the short-lived unmodiﬁed E2
protein expressed without SUMO and Ubc9 was just barely detectable
under these conditions (see ﬁrst lane in each panel of Figs. 2A–C). In
contrast, co-expression of SUMOs 1, 2, or 3 with Ubc9 signiﬁcantly
increased the level of HPV16E2 compared to HPV16E2 expressed alone
(Fig. 2A, left panel). In addition, transfection of any of the SUMOs
alone or of Ubc9 alone can also increase overall intracellular
sumoylation, though to a lesser extent than the combination of
SUMO+Ubc9 (unpublished observations). Consequently, we tested
the effect of the individual SUMOs alone and Ubc9 alone on E2 levels.
Each of the SUMOs was sufﬁcient to enhance E2 levels, and there was
no difference in the E2 levels observed with any of the 3 SUMO types
(Fig. 2A, right panel). Likewise, Ubc9 alone also increased E2 levels
(Fig. 2A, lower panel).
The results in Fig. 2A could reﬂect an inﬂuence of enzymatic
sumoylation on E2 protein or some non-enzymatic effect mediated
through mere expression of the SUMOs or Ubc9 protein. To address
whether or not the effect on E2 levels requires active sumoylation,
two mutants, SUMO1ΔGG and Ubc9(C93S), were tested. SUMO1ΔGG
has a deletion of the C-terminal diglycine motif and is incapable of
being conjugated to substrates (Johnson, 2004) (Fig. 2B, left lower
panel), while Ubc9(C93S) is a catalytically inactive form of Ubc9
(Poukka et al., 1999). Neither of these mutations abrogates interac-
tion between the mutant proteins and sumoylation substrates (Ahn
et al., 2001; Chen et al., 2006; Tomoiu et al., 2006), and both of these
mutant proteins were expressed at levels comparable to their wild-
type forms (Fig. 2B). However, in contrast to their wild-type
counterparts, neither SUMO1ΔGG nor Ubc9(C93S) were able to
increase the level of HPV16E2 (Fig. 2B), consistent with the effect on
E2 requiring active sumoylation and not simply expression of the
sumoylation components.
Since the majority of our studies have been with HPV16E2, it was
important to determine if this effect on E2 levels was restricted to
16E2 (clade A9) or was a more general phenomenon affecting other
HPV type E2 proteins. Consequently, we examined two other mucosal
HPV types, the high risk 18E2 (clade A7) and the low risk 11E2 (clade
A10). As shown in Fig. 2C, levels of both HPV 11E2 and 18E2 were also
increased in the presence of SUMO1 and Ubc9. These positive results
for 3 different clades suggest a general role for sumoylation in
modulating HPV E2 expression levels, at least for mucosal alpha-HPV
types. Whether or not the effect of sumoylation extends to all alpha
types, or to cutaneous HPVs, remains to be determined.
Sumoylation increases E2 levels post-transcriptionally
Next, the mechanism by which sumoylation increased the level of
E2 proteins was investigated. To examine transcriptional effects, semi-
quantitative RT-PCR experiments were performed. E2 transcript levels
were evaluated after 20, 25, 30, and 35 cycles of ampliﬁcation. Fig. 3A
shows the results at 25 cycles, and the level of HPV16E2 mRNA was
unchanged in the presence of the SUMO components. No E2 RNA
signal was detectable at 20 cycles, and the signal intensity for all
samples increased proportionally at both 30 and 35 cycles indicating
that 25 cycles was not saturating (not shown). These results are
consistent with the conclusion that sumoylation was not affecting E2
transcription. Alternatively, E2 proteins are known to be relatively
unstable, so the effect of proteasome inhibition was examined. The
level of HPV16E2 rescued from degradation by a proteasome inhibitor,
ALLN, was similar to that observed with SUMO plus Ubc9 in the
Fig. 2. Sumoylation up-regulates the protein levels of papillomavirus E2. (A) SUMO1, SUMO2, and SUMO3 are able to increase the protein expression of HPV16E2. Left panel: HeLa
cells were transfected with 3 μg of pWEB-16E2 alone (lane 1) or in combination with 1.5 μg of pcDNA5/FRT/TO/HA-Ubc9 and 1.5 μg of either pcDNA5/FRT/TO/His-S-SUMO1,
pcDNA3.1-SUMO2, or pcDNA3.1-SUMO3 as indicated; upper right panel: HeLa cells were transfected with 3 μg of pWEB-16E2 alone (lane 1) or together with 3 μg of either pcDNA5/
FRT/TO/His-S-SUMO1, pcDNA3.1-SUMO2, or pcDNA3.1-SUMO3 as indicated. Bottom right panel: HeLa cells were transfected with 3 μg of pWEB-16E2 alone (lane 1) or together with
3 μg of pcDNA5/FRT/TO/HA-Ubc9. (B) Functional SUMO and Ubc9 are necessary for the stabilization of E2. Left panel: HeLa cells were transfected with 5 μg of pWEB-16E2 alone or
together with 1 μg of either pCS2-GFP-SUMO1WT or pCS2-GFP-SUMO1ΔGG as shown. The position of molecular weight markers is indicated on left side of the panel. Right panel:
HeLa cells were transfected with 3 μg of pWEB-16E2 together with 1.5 μg of pcDNA3.1-SUMO3 alone, or with 1.5 μg of pcDNA3.1-SUMO3 and 1.5 μg of either pcDNA5/FRT/TO/HA-
Ubc9 or pcDNA5/FRT/TO/HA-Ubc9(C93S) [labeled Ubc9⁎ in the ﬁgure] as indicated. (C) Sumoylation increased the expression of HPV11E2 and HPV18E2. HeLa cells were transfected
as indicated using 3 μg of pSG5/HA-11E2, 3 μg pSG5/HA-18E2, 1.5 μg of pcDNA5/FRT/TO/HA-Ubc9, and 1.5 μg of pcDNA5/FRT/TO/His-S-SUMO1. For (A), (B), and (C), carrier pcDNA
plasmid DNA was used to equalize the total DNA amount in all samples. All cells were collected 2 days after transfection, and samples were analyzed by immunoblotting with the
indicated antibodies.
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with SUMO+Ubc9 did not further increase E2 levels above ALLN
alone, consistent with each of these treatments acting through a
similar pathway; identical results were obtained with MG132 (not
shown). These combined results suggest that sumoylation may
protect E2 from the proteasome degradation pathway.
The stabilization of E2 by sumoylation is indirect
One mechanism by which sumoylation could prevent proteosomal
degradation of 16E2 is via competition for the lysine residue targetedfor ubiquitinylation. While the lysine(s) targeted for ubiquitinylation
of 16E2 is unknown, HPV16E2 has a single, predominant sumoylation
site at lysine 292 (Wu et al., 2008), and increased sumoylation levels
might enhance sumoylation of this residue, blocking its usage as an
ubiquitinylation site. To address this question, we examined the effect
of increased sumoylation on wild-type 16E2 versus the E2 K292R
mutant. In the absence of increased sumoylation, the levels of wild-
type and K292R E2 were similarly low (Fig. 4A, left panel).
Surprisingly, co-transfection of SUMO and Ubc9 increased the levels
of the K292R protein comparable to wild-type E2 (Fig. 4A, left panel)
even though we were unable to detect sumoylation of this mutant
Fig. 3. The stabilization of 16E2 by sumoylation is post-transcriptional. (A) The RNA
level of 16E2 does not respond to increased sumoylation. HeLa cells were transfected
with 3 μg of 16E2 alone, or together with 1.5 μg of the SUMO plasmids and 1.5 μg of
either Ubc9 or Ubc9⁎ (the Ubc9 [C93S] mutant) as indicated. Two days after
transfection, total RNA were extracted and subjected to RT-PCR with either 16E2 or
β-actinin primers. (B) Protein degradation inhibitors mimic the stabilization effect of
SUMO expression. HeLa cells were transfected with 3 μg of 16E2 alone or together with
1.5 μg of SUMO3 and 1.5 μg of Ubc9 as indicated. One day after transfection, two of the
four cell cultures were treated with 40 μg/ml of ALLN. At 24 h after the ALLN treatment,
cells were collected, extracts prepared, and the proteins resolved by SDS-PAGE. Western
blotting was performed with the indicated antibodies. For (A) and (B), pcDNA plasmid
DNA was used in these experiments to equalize the total DNA amount of transfected
DNA in each sample.
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right panel) or MG132 (not shown) also increased the wild-type and
mutant E2 proteins to similar levels, indicating that the K292Rmutant
was still susceptible to proteosomal degradation and that lysine 292
was not involved in ubiquitinylation of E2 under normal conditions.
We conclude from these results that the elevated levels of E2 are an
indirect result of increased cellular sumoylation rather than the result
of direct sumoylation of E2 itself.
To further explore the effect of sumoylation on E2 protein, we also
performed in vivo degradation studies to compare the stabilities of
wild-type and K292R mutant 16E2 proteins. After transfection, cells
were treated with cycloheximide to stop further protein synthesis,
and the amount of E2 was determined over time (Figs. 4B and C). Both
wild-type and the K292R mutant 16E2 degraded rapidly at similar
rates and had half-lives of less than 2 h. In contrast, co-expression of
SUMOplus Ubc9 rendered both E2 proteins quite stablewith half-lives
well in excess of 4 h. Thus, sumoylation appears to increase E2 levels
by protecting E2 from proteosomal degradation via a mechanism that
does not require direct sumoylation of E2 at lysine 292. This does not
appear to be a nonspeciﬁc, general response to increased sumoylation
as no signiﬁcant effect on protein levels was observed for two other
viral proteins, E6 (Supplemental Fig. 1) and E1 (Rangasamy et al.,
2000), and for two cellular proteins, C/EBP (see Fig. 1B) and p14ARF
(Supplemental Fig. 1), tested under similar conditions.
Sumoylation blocks the proteasomal degradation of HPV16E2 in vitro
The in vivo observations suggested that sumoylation stabilized E2
by preventing proteasomal degradation. To conﬁrm this conclusion,
we utilized an in vitro ubiquitin and proteasome-dependent degrada-
tion assay. When in vitro translated E2was subsequently incubated for
an additional 4 h in the translation reaction, E2 was relatively stable,
with the majority of the sample remaining as full-length E2 (Fig. 5A,
lanes 1–3). Addition of fresh TNT cell lysate (providing proteasomesand ubiquitinylation enzymes) reduced the amount of full-length E2
somewhat (lanes 7–9) as did addition of exogenous ubiquitin alone
(lanes 4–6). However, addition of both fresh TNT and exogenous
ubiquitin lead to signiﬁcant decrease in full-length E2 within 2 h
(lanes 10–12, and this decrease was blocked by proteasome inhibitors
(ALLN, lanes 13–15 and MG132, not shown), consistent with the loss
of full-length E2 resulting from ubiquitin-dependent proteasomal
degradation. As seen in vivo, addition of the complete sumoylation
reaction components (Sae2/1+Ubc9+SUMO1) to the in vitro system
prevented this degradation of HPV16E2 (Fig. 5B, lanes 7 and 8). No
protection of E2 was observed when only the sumoylation enzymes
without SUMO were added (lanes 5 and 6), consistent with a
requirement for actual sumoylation of some target and not simply
the presence of the enzymatic components. Note that under these
reaction conditions the sumoylation of E2 is undetectable (not
shown), while overall sumoylation of cellular components is efﬁ-
ciently enhanced only when the complete set of sumoylation enzymes
plus SUMO1 are added (Fig. 5C). These data strongly support the
conclusion that sumoylation's role in stabilizing papillomavirus E2
proteins is mediated through the ubiquitin–proteasome pathway via
targeting a factor(s) other than E2 itself. The availability of the
sumoylation-inhibited in vitro degradation system should allow
identiﬁcation of the relevant factor(s) and elucidation of the
mechanism for this effect.
Elevation of endogenous sumoylation stabilizes HPV16E2
The results in the previous sections were observed with exogenous
expression of the sumoylation system both in vivo and in vitro.
However, it would be more biologically relevant to demonstrate that
E2 could be stabilized by endogenous sumoylation under physiologi-
cal conditions. It has been reported that heat shock stress can rapidly
increase the level of SUMO conjugates in cultured mammalian cells
(Mao et al., 2000; Saitoh and Hinchey, 2000), and we used this
approach to evaluate the effect of a physiologic sumoylation increase
on E2 protein. Two days after transfection of HPV16E2, C33A cells
were incubated brieﬂy at 42 °C to increase endogenous sumoylation.
Total cell extracts were collected after various time points and then
analyzed by immunoblotting with antibodies against E2, SUMO1, and
SUMO2/3. Quantitation of the blots indicated that overall endogenous
sumoylation with both SUMO1 and SUMO2/3 increased, reaching a
maximum of approximately 2-fold over basal levels by 2 h after heat
treatment and then slowly diminished (Fig. 6A). As the sumoylation
levels reached theirmaximum, the amount of HPV16E2 in the shocked
cells began to increase while E2 levels in the unshocked control
sample remained unchanged (Figs. 6A and B). By 6 h post-heat shock,
E2 levels had increased 2-fold while in the control cells E2 levels had
declined slightly. These results are consistent with modest physiolo-
gical increases in endogenous sumoylation levels being sufﬁcient to
stabilize the HPV16E2 protein.
Discussion
Both ubiquitination and sumoylation are dynamic post-transla-
tional modiﬁcation processes regulated by functionally equivalent
classes of enzymes. Ubiquitination of BPV and HPV18 E2 proteins
causes their rapid turnover in transfected and infected cells (Bellanger
et al., 2001; Penrose and McBride, 2000), however, the effect of
sumoylation on papillomavirus E2 protein stability had not been
examined. In this work, we identiﬁed a novel effect of sumoylation on
papillomavirus E2 proteins and found that augmented extrinsic or
intrinsic sumoylation indirectly stabilized E2 proteins; a similar
observation of indirect stabilization by sumoylation was recently
reported for the Ku70 protein (Yurchenko et al., 2008). Together with
our previous observation that overall sumoylation levels are increased
during keratinocyte differentiation (Deyrieux et al., 2007), we
Fig. 4. SUMO modiﬁcation of 16E2 is not required for stabilization. (A) Sumoylation had similar stabilizing effects on both 16E2WT and the sumoylation-defective mutant,
16E2K292R. HeLa cells were co-transfected with 3 μg of pWEB-16E2WT or pWEB-16E2K292R, together with 3 μg of pcDNA or with a combination of 1.5 μg of pcDNA5/FRT/TO/HA-
Ubc9 and 1.5 μg of pcDNA3.1-SUMO3 as indicated. One day after transfection, half the samples (right panel) were treated with 40 μg/ml of ALLN and the other half (right panel) were
untreated. Total cell extracts were collected after another 24 h and were processed for immunoblotting as in Fig. 2. (B) HeLa cells were transfected with 3 μg of pWEB-16E2WT or
pWEB-16E2K292R as shown and were also co-transfected with 3 μg of pcDNA (upper panel) or with a combination of 1.5 μg of pcDNA5/FRT/TO/HA-Ubc9 and 1.5 μg of pcDNA3.1-
SUMO2 (bottom panel). Two days after transfection, cells were treated with 200 μg/ml of cycloheximide (CHX), and total cell extracts were collected at the indicated times. Samples
were analyzed by immunoblotting with anti-16E2 or anti-α-tubulin antibodies. The immunoblot for E2 in the upper panel was exposed for a longer time than those in the previous
ﬁgures and in the lower panel in order to allow visible detection of E2 in the absence of SUMO plus Ubc9; absolute levels of E2 at time 0 in the upper panel are actually much less than
in the lower panel. (C) The samples shown in part (B) were quantitated by densitometry and the 16E2 amounts were normalized to α-tubulin.
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E2 in the upper layers of differentiated epithelium. Furthermore, in
addition to differentiation-dependent changes in sumoylation,
sumoylation levels are inﬂuenced by a variety of cellular stresses
(Agbor and Taylor, 2008; Gill, 2004), raising the intriguing possibility
that E2 levels in infected skin could be affected by such things as
trauma, UV exposure, hypoxia, or hormonal changes. Regulating E2
stability by overall sumoylation levels could provide ameans to couple
viral replication and transcription to environmental conditions that
affect the cellular state. Whether or not such effects contribute to HPV
persistence, disease manifestation, or malignant progression with
high-risk viruses remains to be tested.
SUMOs have been shown to conjugate covalently to a variety of
proteins that have signiﬁcant roles in gene expression, chromatin
structure, signal transduction, and genome maintenance, and can
inﬂuence the activity and intracellular localization of these proteins
(Gill, 2004). In addition, sumoylation can also modulate the turnover
of certain substrates, and in some cases increases the stability of target
proteins by direct modiﬁcation of these substrates. However, for E2
proteins we observed that the K292R mutant, which is not detectably
sumoylated, was efﬁciently stabilized in vivo, indicating that sumoyla-
tion was acting indirectly and not through direct modiﬁcation of E2.
The stabilizing effect of sumoylation could be recapitulated in an in
vitro degradation system under conditions where wild-type E2 was
not detectably sumoylated. Since E2 itself does not need to be
sumoylated either in vivo or in vitro, this indicates that sumoylation
must be acting on some other cellular substrate(s) that inﬂuences E2
stability, possibly members of the ubiquitin pathway itself. The
ubiquitinylation machinery consists of two activating enzymes,
approximately thirty ubiquitin conjugating enzymes, numerousubiquitin ligases, and a variety of deubiquitinylating enzymes; the
speciﬁc components involved in E2 degradation have not been
deﬁned. Any of the components involved in the ubiquitinylation
pathway could be targets for sumoylation, and their modiﬁcation by
SUMO could impair their ability to utilize papillomavirus E2 proteins
as substrates for ubiquitinylation, leading to increased E2 stability.
Consistent with this possibility, sumoylation of both a ubiquitin
conjugating enzyme (Pichler et al., 2005) and a ubiquitin ligase
(Xirodimas et al., 2002) has already been reported, and there is
growing evidence of extensive cross-talk between the ubiquitin and
SUMO systems (Wilson and Heaton, 2008). Conversely, sumoylation
could be targeting a deubiquitinylating enzyme causing enhanced
activity towards ubiquitinylated E2 and leading to increased removal
of ubiquitin with subsequent stabilization of E2.
An alternative to targeting the ubiquitin pathway directly would be
for sumoylation to affect another modiﬁcation of E2 that is necessary
for ubiquitinylation. While relatively little is known about phosphor-
ylation of HPV E2 proteins, it is clear that BPV E2 degradation is
triggered by phosphorylation via casein kinase II (Penrose et al.,
2004). Therefore, another possible mechanism for sumoylation to
prevent HPV E2 protein degradation would be to modify and
inactivate a requisite kinase (or conversely activate an appropriate
phosphatase), and thus reduce a critical degradation signal. Interest-
ingly, pilot experiments have shown that casein kinase II can be
sumoylated in vivo (Wu and Wilson, unpublished observations),
which is consistent with the possibility that SUMO addition could
regulate the enzyme activity of casein kinase II and possibly other
kinases. Lastly, E2 has many cellular binding partners, including Brd4
(McPhillips et al., 2006; You et al., 2004), p53 (Massimi et al., 1999),
TopBP1 (Donaldson et al., 2007), and many transcriptional factors
Fig. 5. The degradation of HPV16E2 was inhibited by sumoylation. (A) The in vitro
degradation assay of 16E2 was performed as described in Materials and methods. In
vitro translated 16E2 was incubated at 30 °C for 0, 2, or 4 h with buffer alone (lanes 1–3)
or the indicated components (lanes 4–15). After incubation, each reaction was
terminated with SDS-sample buffer, the samples were resolved by 10% SDS-PAGE,
and then transferred to PVDF membrane for visualization with a phosphorimager.
Molecular weight marker positions are indicated on the left side of the ﬁgure. (B) The
reaction and analysis was performed as in part (A) except that the samples were
incubated for 0 or 2 h prior to termination and analysis as indicated. Addition of the
Ub+TNT and puriﬁed sumoylation components is as indicated. The position of
molecular weight markers is shown on the left side of the ﬁgure. Samples in this
experiment were resolved on an 8% SDS-PAGE gel and run longer to resolve the E2
cleavage species that runs just below full-length E2. (C) The in vitro degradation
reaction samples were analyzed by immunoblotting with anti-SUMO1. All samples
contained Ub, TNT, and E2 comparable to lanes 7 and 8 in panel B. Samples were
incubated for 2 h at 30 °C prior to termination and immunoblot analysis.
Fig. 6. HPV16E2 is stabilized by elevated endogenous sumoylation. (A) C33A cells were
transfected with pWEB-16E2 and then heat-shocked by incubation at 42 °C for 1 h at
2 days after transfection or left continuously at the normal temperature of 37 °C. Protein
samples were collected at 1-hour time intervals and then analyzed by immunoblotting
with anti-16E2 or SUMO-speciﬁc antibodies. The E2 samples were quantiﬁed by
densitometry and the 16E2 amounts were normalized toα-tubulin. The zero time point
E2 values for the heat-shocked (♦) and unshocked (▾) samples were set as 1.0, and the
subsequent E2 amounts are relative to the zero time point values. A similar analysis was
performed using anti-SUMO1 (▪) and anti-SUMO2/3 (▴) antibodies to measure total
sumoylation by SUMO1 and SUMO2/3 in the heat-shocked samples. The data shown are the
average of three experiments. The arrow indicates the time when sumoylation has reached
maximum levels. (B) A representative immunoblot for E2 and tubulin for heat shocked (upper
panel) and non-shocked (lower panel) cultures.
181Y.-C. Wu et al. / Virology 387 (2009) 176–183such as YY1 (Lee et al., 1998) and C/EBP (Hadaschik et al., 2003).
Sumoylation of any of the E2 partners could inﬂuence complex
formation and lead to reduced E2 accessibility to the proteasomal
machinery. Both this accessibility mechanism and the phosphoregu-
latorymodelwould of course require that the appropriate factors were
present in the in vitro degradation reactions. Given the complexity of
the TNT mixture, this is certainly a possibility, though it remains
untested.
In summary, there are multiple potential targets through which
sumoylation could prevent E2 degradation, both within the ubiquitin
pathway and external to it. Regardless of the target(s), it is clear from
the work presented here that changes in sumoylation levels can
dramatically impact the stability of E2 proteins. Much additional work
will be required to resolve the mechanism of action and to determine
if this is a general mechanism that can regulate stability of proteins
other than E2.Materials and methods
Plasmids
Plasmids utilized in this study were generously provided by the
following: pSG5/HA-11E2, pSG5/HA-16E2 and pSG5/HA-18E2 by Dr.
S.M. Huang; pWEB-16E2 by Dr. K. Gaston; pcDNA3.1/HA-SUMO2,
pcDNA3.1/HA-SUMO3, and the GST-SAE1/SAE2 expression plasmid
by Dr. Ronald T. Hay; pCS2-GFP-SUMO1WT and pCS2-GFP-
SUMO1ΔGG by Dr. Ryan Potts; and pcDNA3.1-C/EBPβ by Dr. Linda
Sealy. The pRSET-SUMO1 plasmid (Rosas-Acosta et al., 2005a), and the
pcDNA5/FRT/TO/His-S-SUMO1, pcDNA5/FRT/TO/HA-Ubc9 and
pcDNA5/FRT/TO/HA-Ubc9(C93S) plasmids have all been described
previously (Rosas-Acosta et al., 2005b).
Cell culture, transfection and reagents
HeLa cells were maintained and grown in Dulbecco MEM (DMEM)
supplemented with 10% Fetal Bovine Serum (FBS) and 45 mM of
sodium bicarbonate. C33A cells were maintained and grown in DMEM
supplemented with 10% FBS and 18 mM of sodium bicarbonate. Both
cell lines were maintained at 37 °C and 5% CO2 in a humidiﬁed
incubator. For transfections, 90% conﬂuent cells in 6-well plates were
transfected using a total of 6 μg of DNA and 6 μl of Lipofectamine 2000
(Invitrogen) according to the supplier's recommendations. Two days
after transfection, the HeLa or C33A cells were collected by addition of
500 μl of SDS-sample buffer (150 mM Tris–HCl, pH 6.8, 12% SDS, 30%
glycerol). These samples were passed through a 26 ga syringe and
denatured at 95 °C for 7 min. Then, 30 μl of each sample were resolved
by SDS-PAGE followed by immunoblot analysis as previously
described (Wu et al., 2008). Cycloheximide (Sigma) and the calpain
182 Y.-C. Wu et al. / Virology 387 (2009) 176–183protease inhibitor, ALLN (Calbiochem), were used at the concentra-
tions indicated in the ﬁgure legends.
Immunoblotting
Primary antibodies used in this manuscript were: mouse anti-
α-tubulin (1:5000, Santa Cruz), mouse anti-HPV16E2 (1:1000,
Santa Cruz), rabbit anti-SUMO1 and anti-Ubc9 serum (1:1000;
Deyrieux et al., 2007), mouse anti-HA (1:10,000, Santa Cruz), mouse
anti-GFP (1:5000, Santa Cruz), and rabbit anti-SUMO3 (1:200,
Zymed). Samples were analyzed by SDS-PAGE and were immuno-
blotted as previously described (Wu et al., 2008).
RT-PCR
Total RNAs were extracted using the RNAqueous kit (Ambion)
and were stored at −80 °C until use. The Superscript III RT-PCR
was performed with a mixture containing 50 ng of RNA in a ﬁnal
reaction volume of 25 μl according to the manufacturer's instruc-
tions (Invitrogen). RT-PCR was performed for 30 min at 55 °C for
the reverse transcription step, followed by 2 min at 94 °C, and 20,
25, 30, or 35 cycles of ampliﬁcation (94 °C for 15 s; 60 °C for 30 s;
68 °C for 20 s). Ampliﬁed products were analyzed on 1% agarose
gels and visualized with an Innotech Alphaimager system (Alpha
Innotech).
In vitro degradation assay
The HPV16E2 protein was expressed from the pSG5/HA-16E2
plasmid using the T7-coupled rabbit reticulocyte lysate system in
the presence of [35S] methionine according to the manufacturer's
instructions (Promega). All sumoylation components were
expressed and puriﬁed as described previously (Rosas-Acosta et
al., 2005a). For the degradation assay, 2 μl of 35S-labeled protein
was mixed with or without 10 μg of ubiquitin (Sigma), and 4 μl of
reticulocyte lysate (TNT, Promega). Where indicted in the ﬁgures,
some samples also received 2 μg of SAE2/SAE1, 1 μg of Ubc9, and
5 μg of SUMO1. All the reactions were performed for the indicated
times at 30 °C in a ﬁnal buffer volume of 25 μl containing 25 mM
Tris, pH 7.5, 60 mM NaCl, 8 mM MgCl2, 4 mM ATP, and 1 mM DTT.
Ten microliters of SDS-sample buffer were added to each sample to
stop the reaction. For the degradation assay, mixtures were prepared
as for the ubiquitinylation assay and then divided into two halves. One
of half was mixed immediately with 12.5 μl of SDS-sample buffer, and
the other half was further incubated at 30 °C for another 2 h before
addition of the SDS-sample buffer. All samples were incubated at
95 °C for 7 min and then were analyzed by SDS-PAGE. Radiolabeled
bandswere visualized by phosphorimagingwith a Storm860 (General
Electric).
Heat shock experiment
C33A cells grown at 37 °C were transferred to 42 °C, incubated
for 1 h at this elevated temperature, and then returned to the 37 °C
incubator. Total cell extracts were collected with 500 μl of SDS-
sample buffer every hour for 6 h, and the samples were analyzed
by immunoblotting for total sumoylation and for E2 protein.
Relative quantities of E2 and total sumoylation were obtained by
densitometry of the X-ray ﬁlms using α-tubulin as the internal
standard. For the total sumoylation quantiﬁcation, the signal for
each entire lane was summed using the Alpha Innotech 1D-Multi
software.
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